This announcement leads to a very technical detail related to...

This announcement leads to a very technical detail related to bioavailability. It has been known for at least 6 + years that MPL has poor solubility in water. This can be overcome by using dichlormethane / ethanol to give you a soluble but safe product. I don't think the pure word of solubility is the problem.

My interpretation of the announcement is that Leiden are having a procedural problem in getting the correct bioavailability to the target organ. In this case scenario we need to get the drug to the stratified columnar epithelium in the upper airways. MPL has good bioavailability in relation to muscle /subcutaneous fat /liver and kidney.

We are all aware as an anti cancer agent it is probably proven. Due to its mTOR inhibition mainly. Can it kill Covid
19 . Yes , if we can get it to the target. Problem is the location we are asking to get the drug to. The upper airway is a highly dense cell mass to permeate. Especially the bases of the cells. We have one of the top 16 Universities in the world that specialises in this domain. We must hope and pray that they will overcome this distribution problem.

So in precis, I have said before that MPL works on two types of lung cancer. The cell lineage of the lungs are more of a single layer, whereas the cell lining of the upper airway is double triple quadruple layers making it hard for our drug to dissolve through these dense cells to achieve the goal. What's our goal ,to get MPL to the site so it's anti parasitic action can stop the virus from mutating exactly on entry to our body.

Stay tuned be patient. The best of "us" are working hard on achieving this.

If it works I am sure we will drop the word " armamentarium" and "inappetance " at our next dinner engagement. Good luck fellow hot copperites we are close. Remember it anecdotally worked for Mickey Mouses friends.